Valuation : Mymetics Corporation

Market Cap 439K 377K 356K 324K 606K 41.95M 612K 4.24M 1.63M 21.28M 1.65M 1.61M 67.58M P/E 2021
-1.86x
P/E 2022 -1.77x
Enterprise Value 72.12M 62.03M 58.52M 53.31M 99.66M 6.9B 101M 697M 268M 3.5B 271M 265M 11.11B EV / Sales 2021
177x
EV / Sales 2022 78x
Free-Float
99.88%
Yield 2021 *
-
Yield 2022 -
1 day+45.45%
1 week+1,066,566.67%
Current month+1,066,566.67%
1 month+1,066,566.67%
3 months+1,066,566.67%
6 months+1,066,566.67%
Current year+1,066,566.67%
Current year 0
Extreme 0.0003
3.2
1 year 0
Extreme 0.0003
3.2
3 years 0
Extreme 0.0003
5.6
5 years 0
Extreme 0.0003
230
10 years 0
Extreme 0.0003
380
Manager TitleAgeSince
Chief Executive Officer 58 18/11/2012
Change 5-day change 1-year change 3-year change Capi.($)
+45.45%+1,066,566.67%+1,066,566.67%-40.74% 45
-0.25%-1.36%+44.08%+102.76% 68.24B
+0.19%-4.19%+30.76%+74.13% 62.23B
-1.18%+0.47%-12.78%+384.69% 27.8B
-1.64%-5.00%+29.78%+9.41% 24.86B
-1.76%-6.30%-4.55%-19.75% 24.22B
+0.07%-3.88%+14.25%-19.71% 19.36B
-1.86%-2.22%+202.03%+353.89% 17.28B
-1.85%-4.86%-5.21%+496.16% 14.46B
-1.54%-2.88%+52.33%+159.75% 14.23B
Average +3.55%-2.97%+106,691.73%+150.06% 27.27B
Weighted average by Cap. -0.77%-3.10%+35.33%+136.63%

Financials

2021 2022
Net sales 430K 370K 349K 318K 594K 41.11M 600K 4.16M 1.6M 20.85M 1.61M 1.58M 66.23M 1.03M 884K 834K 760K 1.42M 98.28M 1.43M 9.93M 3.82M 49.85M 3.86M 3.78M 158M
Net income -4.73M -4.07M -3.84M -3.5M -6.54M -452M -6.6M -45.71M -17.59M -229M -17.76M -17.37M -729M -4.8M -4.13M -3.9M -3.55M -6.64M -459M -6.7M -46.43M -17.87M -233M -18.04M -17.65M -740M
Net Debt 67.1M 57.71M 54.45M 49.6M 92.72M 6.42B 93.56M 648M 250M 3.25B 252M 246M 10.34B 71.68M 61.65M 58.17M 52.99M 99.06M 6.85B 99.96M 693M 267M 3.48B 269M 263M 11.04B
Logo Mymetics Corporation
Mymetics Corporation is a vaccine company. The Company is focused on developing vaccines for infectious diseases. The Company has over five vaccine candidates in its pipeline: human immunodeficiency virus type 1 (HIV-1)/acquired immune deficiency syndrome (AIDS), intra nasal Influenza, Malaria, Herpes Simplex Virus (HSV) and the Respiratory Syncitial Virus (RSV) vaccine. Its technology utilizes virosomes, lipid-based carriers containing functional fusion viral proteins and natural membrane proteins, in combination with rationally designed antigens. Its prophylactic HIV-1 vaccine candidate is constituted of virosomes linked to conserved antigens derived from the HIV-1 glycoprotein 41 (gp41) proteins from the clade B. The RSV vaccine consists of the reconstituted membrane of RSV containing the native viral proteins. The HSV vaccine candidate consists of the reconstituted membrane of HSV-1 or HSV-2. The intranasal influenza vaccine includes the reconstituted membrane of influenza virus.
Employees
-
  1. Stock Market
  2. Stocks
  3. MYMX Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!